Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
ABBV-744 (ABBV744) is a novel, potent and highly BDII-selective BET bromodomain inhibitor with anticancer and anti-inflammatory activity. As a BDII-selective BET bromodomain inhibitor, it is under investigation for the treatment of AML and metastic castration-resistant prostate cancer. It also has the potential to be used in the treatment of inflammatory diseases and AIDS.
Targets |
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
In comparison to ABBV-075 [1], ABBV-744 (4.7 mg/kg; interfacial gavage; 28 days) shown comparable or superior anti-tumor effectiveness and retarded the formation of tumors. /kg; 14) has strong anti-tumor properties. By 20%, ABBV-744 (30 mg/kg) suppresses interference [1].
|
|
Animal Protocol |
Animal/Disease Models: Mouse
Doses: 4.7 mg/kg (pharmacokinetic/PK/PK analysis) Dosing: po (oral gavage); 28-day Experimental Results: compared with ABBV-075, caused tumor growth delay and demonstrated the same or better anti- tumor activity. Animal/Disease Models: SD (SD (Sprague-Dawley)) rat Doses: 30 mg/kg (pharmacokinetic/PK/PK analysis) Dosing time: 14 days Experimental Results: Produced significant anti-tumor activity. |
|
References |
[1]. Faivre EJ, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578(7794):306-310.
|
Molecular Formula |
C28H30FN3O4
|
---|---|
Molecular Weight |
491.5539
|
CAS # |
2138861-99-9
|
SMILES |
O=C(C(N1)=CC(C(C2=CC(C(C)(O)C)=CC=C2OC3=C(C)C=C(F)C=C3C)=CN4C)=C1C4=O)NCC
|
InChi Key |
OEDSFMUSNZDJFD-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
|
Chemical Name |
N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
|
Synonyms |
ABBV744; ABBV 744; ABBV-744.
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~203.44 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0344 mL | 10.1719 mL | 20.3438 mL | |
5 mM | 0.4069 mL | 2.0344 mL | 4.0688 mL | |
10 mM | 0.2034 mL | 1.0172 mL | 2.0344 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.